$4 Million Perelman Foundation Donation to Kick-start Myeloma Research Initiative
The first research program dedicated to the early detection and prevention of multiple myeloma will be under way soon, thanks to a $4 million Perelman Family…
News
Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma
Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab), according…
Keytruda Seen to Increase Efficacy of Pomalyst and Dexamethasone in Myeloma Trial
A Phase 2 trial has shown that Keytruda (pembrolizumab) increases the effectiveness of Pomalyst (pomalidomide) and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). The study…
Bluebird to Present Follow-Up Data for CAR T-cell Therapy in Advanced Multiple Myeloma Patients
Patients with advanced multiple myeloma who received three or more lines of therapy have shown promising safety and efficacy…
Genmab-Janssen Venture to Launch 3 Clinical Trials of Multiple Myeloma Therapy Darzalex
Genmab announced that its partner Janssen Biotech will launch three novel studies to investigate the effect of Darzalex (daratumumab) in patients with multiple…
Non-profit Cancer Therapy Consultant Patient Power Praises District of Columbia Law Limiting Co-pays
The non-profit cancer-therapy consulting group Patient Power is hailing a District of Columbia law that established patient co-pay ceilings on specialty medications for diseases like multiple myeloma.
Myeloma Advocacy Group Criticizes House Passage of American Health Care Act
The International Myeloma Foundation (IMF) says it is deeply worried that the American Health Care Act (AHCA) — which narrowly passed the U.S. House of…
Documentary Chronicles Record Run for a Departed Friend and Myeloma Research
A new documentary, “200 Miles,” tells the inspiring story of ultra-marathoner Eric Gelber’s determination to complete 33 loops of New York’s Central Park to…
Switzerland Grants PharmaMar’s Aplidin Orphan Drug Status to Treat Multiple Myeloma
Switzerland’s Agency for Therapeutic Products (Swissmedic) has awarded PharmaMar’s Aplidin orphan drug status to treat patients with multiple myeloma, following a similar designation by the U.S. Food…
One World Cannabis to Test Mice in Pursuit of Therapies Targeting Multiple Myeloma Cancer Cells
Israel’s One World Cannabis (OWC) says it’s moving forward to mouse models to test its unique formula of cannabinoid-based therapies targeting cancer cells. This decision followed promising results…
